Johnson & Johnson agreed to pay $1.75 billion to acquire privately held Alios BioPharma Inc., a developer of experimental treatments for viral diseases including hepatitis C.

Aligos Therapeutics, a startup headed by entrepreneurs who led venture-backed Alios BioPharma to a $1.75 billion merger with Johnson & Johnson in 2014, has raised $125 million to develop ...

With the help of new investor SR One, the corporate venture fund of GlaxoSmithKline, Alios BioPharma has raised an additional $8 million to advance its preclinical programs toward proof-of-concept.

SOUTH SAN FRANCISCO, CA -- 06/11/09 -- Alios BioPharma, Inc. announced today that it has closed its $32 million Series A preferred stock financing with $8 million from new investor SR One, the ...

As of last August, 700,000 AliOS-powered SAIC vehicles had been sold. Techcrunch event. Save $450 on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper.

Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, today announced a definitive agreement with Johnson & Johnson whereby Alios will be ...

Johnson & Johnson plans to acquire Alios BioPharma for $1.75 billion cash, in a deal that will expand the pharma giant’s viral-disease portfolio with two Phase II drugs and several preclinical ...

Alios also secured 100 percent financing from Vertex for all future development costs required to take the related programs all the way through development and commercialization. Alios retains the ...

On Tuesday, Johnson & Johnson (JNJ) announced that the company had plans to add Alios BioPharma, a private biotechnology company focused on treating viral diseases, to its assets. Alios BioPharma ...

Alios BioPharma will become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson. The acquisition includes Alios BioPharma’s portfolio of ...

Johnson & Johnson of New Brunswick, New Jersey, has snapped up Bay Area-based Alios BioPharma for $1.75 billion in cash. Founded in 2008 by three executives from InterMune, Alios had previously ...